SUMMARY: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Rare endocrine irAEs are diabetes insipidus, hypoparathyroidism, thyrotoxic crisis and hypogonadism. We report a case of hypoparathyroidism induced by ICI treatment with durvalumab, which has not previously been described. LEARNING POINTS: Treatment with immune checkpoint inhibitors (ICIs) is associated with many endocrine side effects.It is recommended that patients treated with ICIs are observed by an endocrinologist.If side effects are treated accordingly, ICI therapy can continue.

Department of Biochemistry The Bulovka University Hospital Praha Czech Republic

Department of Internal Medicine The Bulovka University Hospital Praha Czech Republic

Endocrine Clinic of Internal Medicine Department The Bulovka University Hospital Praha Czech Republic

See more in PubMed

Burke KP, Grebinoski S, Sharpe AH, Vignali DAA.2020Understanding adverse events of immunotherapy: a mechanistic perspective. Journal of Experimental Medicine 1 e20192179. (10.1084/jem.20192179) PubMed DOI PMC

Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre Oet al.2019French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocrine-Related Cancer 26G1–G18. (10.1530/ERC-18-0320) PubMed DOI PMC

Cubb T, Patel Set al.2017Primary hypoparathyroidism: a new endocrine immune related adverse event (irAEs) secondary to combination treatment with PD-1 and CLA-4 checkpoint inhibitors. Endocrine Reviews 38 (Supplement 1). (10.1093/edrv/38.supp.1) DOI

Dadu R, Rodgers TE, Trinh VA, Kemp EH, Cubb TD, Patel S, Simon JM, Burton EM, Tawbi H.2020Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. Journal for ImmunoTherapy of Cancer 8 e000687. (10.1136/jitc-2020-000687) PubMed DOI PMC

Deligiannis NG, Sosa S, Danilowicz K, Rizzo LFL.2021Endocrinne dysfunction induced by immune checkpoint inhibitors. Medicina 81269–278. PubMed

Edd T, Taufeeq M, Buschur E.2018Nivolumab induced hypoparathyroidism. Endocrine Reviews 39 (Supplement 1). (10.1093/edrv/39.supp.1) DOI

El Kawkgi OM, Li D, Kotwal A, Wermers RA.2020Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy. Mayo Clinic Proceedings 4821–825. (10.1016/j.mayocpiqo.2020.07.006) PubMed DOI PMC

George AS, Fernandez CJ, Eapen D, Pappachan JM.2021Organ-specific adverse events of immune checkpoint inhibitor therapy, with special reference to endocrinopathies. TouchREVIEWS in Endocrinology 1721–32. (10.17925/EE.2021.17.1.21) PubMed DOI PMC

Hattersley R, Nana M, Lansdown AJ.2021Endocrine complications of immunotherapies: a review. Clinical Medicine 21e212–e222. (10.7861/clinmed.2020-0827) PubMed DOI PMC

Khan OF, Monzon J.2020Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. Current Oncology 27S43–S50. (10.3747/co.27.5111) PubMed DOI PMC

Lupi I, Brancatella A, Cetani F, Latrofa F, Kemp EH, Marcocci C.2020Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 1051581–1588. (10.1210/clinem/dgaa092) PubMed DOI

Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N.2019Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. Journal of Clinical Endocrinology and Metabolism 104550–556. (10.1210/jc.2018-01151) PubMed DOI

Trinh B, Sanchez GO, Herzig P, Läubli H.2019Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. Journal for ImmunoTherapy of Cancer 7 52. (10.1186/s40425-019-0528-x) PubMed DOI PMC

Umeguchi H, Takenoshita H, Inoue H, Kurihara Y, Sakaguchi C, Yano S, Hasuzawa N, Sakamoto S, Sakamoto R, Ashida K.2018Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report. Journal of Oncology Practice 14449–451. (10.1200/JOP.18.00076) PubMed DOI

Win MA, Thien KZ, Qdaisat A, Yeung SJ.2017Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. American Journal of Emergency Medicine 351039.e5–1039.. (10.1016/j.ajem.2017.02.048) PubMed DOI